BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 12942558)

  • 1. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.
    Yoh K; Goto K; Ishii G; Niho S; Ohmatsu H; Kubota K; Kakinuma R; Nagai K; Suga M; Nishiwaki Y
    Cancer; 2003 Sep; 98(5):926-31. PubMed ID: 12942558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
    Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
    Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
    Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
    J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
    Yuen AR; Fuks JZ; Ettinger DS; Chang AY; Ruckdeschel JC; Phan SC; Blum RH
    Cancer J Sci Am; 2000; 6(1):34-9. PubMed ID: 10696737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.
    Lucchi M; Ambrogi MC; Duranti L; Basolo F; Fontanini G; Angeletti CA; Mussi A
    Ann Thorac Surg; 2005 Jun; 79(6):1840-4. PubMed ID: 15919267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience.
    Berruti A; Borasio P; Gerbino A; Gorzegno G; Moschini T; Tampellini M; Ardissone F; Brizzi MP; Dolcetti A; Dogliotti L
    Br J Cancer; 1999 Nov; 81(5):841-5. PubMed ID: 10555755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
    Chamberlain MC; Glantz MJ
    Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
    Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.